MedTrace Logo

Effects of GLP-1 on Chronic Heart Failure

NCT02650596 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2016-01-08

No results posted yet for this study

Summary

The investigators planned to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

Conditions

Interventions

DRUG

GLP-1

Liraglutide were taken daily for 3 months

DRUG

Placebo

Placebo were taken daily for 3 months

Sponsors & Collaborators

  • Shi Yang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02650596 on ClinicalTrials.gov